MD+DI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Medtech in a Minute: COVID-19 Impacts Business, Regulation, and More

Image by OpenClipart-Vectors on Pixabay Medtech in a Minute: COVID-19 Impacts Business, Regulation, and More
Your time is valuable, so we've drilled down the three most important medtech stories from the past week. But feel free to click the headline to read beyond the blurb.
Pressed for time? Here's the medtech news you need most, in one minute or less.

EC pushes to postpone new medical device regulations 

As the deadline for the new medical device regulations to go into force in the European Union rapidly approaches (end of May), the European Commission (EC) is looking to postpone the new regulations by one year. The delay would allow national authorities and industry to focus on urgent priorities related to the coronavirus (COVID-19) crisis, said a spokesman for the EC.

Elon Musk Talks Ventilators with Medtronic

Tweets from Elon Musk and Medtronic attracted a lot of positive and negative attention. Musk said he "had a long engineering discussion with Medtronic about state-of-the-art ventilators." Medtronic said it is grateful for the discussion with Musk and Tesla as the company works across industries to solve problems associated with the coronavirus pandemic.

COVID-19 triggers furloughs at one medtech company, strategic exploration at another

Conformis is furloughing one-third of its workforce (about 80 employees) citing a sharp decline in elective procedures because of the COVID-19 pandemic. The custom orthopedics implant company also withdrew its previous 2020 product revenue growth target of 3% to 6%. Meanwhile, Obalon Therapeutics is exploring financial and strategic alternatives for the same reason. The weight-loss device maker said these alternatives could include equity or debt financing; a sale of the company; a business combination; or a merger or reverse merger with another party.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.